DN Investor
investor.dn.noKonsernsjef Martin Olin har kjøpt 9.100 aksjer i BerGenBio til kurs 20,51 kroner pr aksje, ifølge en melding mandag. Etter transaksjonen eier Olin 37.100 aksjer i selskapet. BERGENBIO
BerGenBio - Developing first-in-class AXL inhibitors for ...
www.bergenbio.comDec 16, 2021 · BERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2021. Bergen, Norway, 16 February 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announces its results for the fourth quarter and full year 2021. A briefing.
BERGENBIO (BGBIO) aksje - Nordnet
www.nordnet.no › market › stocksSvalKapital. 16. feb. · Vis innlegg. BERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2021 Bergen, Norway, 16 February 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical nee.